Qianjiang Yongan Pharmaceutical Co., Ltd. (SHE:002365)

Market Cap	3.96B +59.3%
Revenue (ttm)	783.17M -6.6%
Net Income	22.49M -63.6%
EPS	0.08 -62.9%
Shares Out	289.15M
PE Ratio	176.32
Forward PE	n/a
Dividend	0.10 (0.76%)
Ex-Dividend Date	Jul 9, 2025

Volume	17,824,863
Average Volume	6,836,041
Open	13.12
Previous Close	13.22
Day's Range	13.12 - 14.09
52-Week Range	10.61 - 32.14
Beta	0.61
RSI	51.95
Earnings Date	Apr 17, 2026

About SHE:002365

Qianjiang Yongan Pharmaceutical Co., Ltd. engages in production and sale of taurine in China. It produces ethylene oxide, polycarboxylic acid-based water reducer monomers, water reducers, and health products. The company engages in scientific research and technical service, creatine monohydrate, wholesale and retail trade, leasing and business services, and crop farming. Qianjiang Yongan Pharmaceutical Co., Ltd. was founded in 2001 and is based in Qianjiang, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2001
• Employees: 930
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002365

Financial Performance

In 2025, SHE:002365's revenue was 783.17 million, a decrease of -6.63% compared to the previous year's 838.81 million. Earnings were 22.49 million, a decrease of -63.58%.